Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Immuno-Grade GPR63 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
GPR63 (IHC-Grade), G protein-coupled Receptor 63 Antibody
GPR63 (IHC-Grade), G protein-coupled Receptor...
The non-phospho-GPR63 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR63. It can be used to detect total GPR63 receptors in Western blots independent of phosphorylation. The GPR63 antibody...
375.00 € *

G protein-coupled receptor 63 (GPR63, formerly PSP24β) is a class A orphan receptor whose physiological ligand remains unknown. Sphingosine 1-phosphate and dioleoylphosphatidic acid have been reported to activate GPR63 at submicromolar concentrations in heterologous expression systems. These responses were not reproduced in a β-arrestin recruitment assay, and the physiological relevance of either lipid as a GPR63 agonist remains uncertain. GPR63 transcripts have been detected in the human brain, including the frontal cortex, thalamus, caudate nucleus, hypothalamus, and midbrain. In cultured cells, recombinant mouse GPR63 localizes to primary cilia, suggesting that the receptor may participate in ciliary signaling. A naturally occurring Gpr63 variant modifies the severity of microcephaly in mice carrying a mutation in the ciliary transport gene Ttc21b, linking GPR63 to brain development in this genetic context. The receptor’s native G protein coupling and the mechanisms governing its trafficking and desensitization remain poorly characterized. No GPR63-selective ligand has been reported to enter clinical trials or to be approved for therapeutic use. For more information on GPR62 pharmacology please refer to the IUPHAR database. For further reading refer to: 

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

G protein-coupled receptor 63 (GPR63, formerly PSP24β) is a class A orphan receptor whose physiological ligand remains unknown. Sphingosine 1-phosphate and dioleoylphosphatidic acid have been... read more »
Close window
Immuno-Grade GPR63 Receptor Antibodies

G protein-coupled receptor 63 (GPR63, formerly PSP24β) is a class A orphan receptor whose physiological ligand remains unknown. Sphingosine 1-phosphate and dioleoylphosphatidic acid have been reported to activate GPR63 at submicromolar concentrations in heterologous expression systems. These responses were not reproduced in a β-arrestin recruitment assay, and the physiological relevance of either lipid as a GPR63 agonist remains uncertain. GPR63 transcripts have been detected in the human brain, including the frontal cortex, thalamus, caudate nucleus, hypothalamus, and midbrain. In cultured cells, recombinant mouse GPR63 localizes to primary cilia, suggesting that the receptor may participate in ciliary signaling. A naturally occurring Gpr63 variant modifies the severity of microcephaly in mice carrying a mutation in the ciliary transport gene Ttc21b, linking GPR63 to brain development in this genetic context. The receptor’s native G protein coupling and the mechanisms governing its trafficking and desensitization remain poorly characterized. No GPR63-selective ligand has been reported to enter clinical trials or to be approved for therapeutic use. For more information on GPR62 pharmacology please refer to the IUPHAR database. For further reading refer to: 

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed